meai

Video: meai

      MEAI GudangMovies21 Rebahinxxi LK21

      MEAI, also known as 5-methoxy-2-aminoindane (5-MeO-AI), is a monoamine releasing agent of the 2-aminoindane group. It specifically acts as a selective serotonin releasing agent (SSRA). The drug is under development for the treatment of alcoholism, cocaine use disorder, metabolic syndrome, and obesity under the developmental code name CMND-100.


      Effects


      When used recreationally, MEAI is reported to produce mild psychoactive effects and euphoria.


      Pharmacology




      = Pharmacodynamics

      =
      MEAI is a monoamine releasing agent (MRA). It is a modestly selective serotonin releasing agent (SSRA), with 6-fold preference for induction of serotonin release over norepinephrine release and 20-fold preference for induction of serotonin release over dopamine release. In addition to inducing monoamine neurotransmitter release, MEAI has moderate affinity for the α2-adrenergic receptor. Based on these findings, MEAI might produce MDMA-like entactogenic and sympathomimetic effects but may be expected to have reduced misuse liability in comparison.


      Chemistry


      MEAI, also known as 5-methoxy-2-aminoindane, is a 2-aminoindane derivative. It is the 2-aminoindane analogue of the amphetamine 3-methoxyamphetamine.


      History


      MEAI appears to have been first synthesized in 1956.
      Its molecular structure was first mentioned implicitly in a markush structure schema appearing in a patent from 1998. It was later explicitly and pharmacologically described in a peer reviewed paper in 2017 by David Nutt and Ezekiel Golan et al. followed by another in February 2018 which detailed the pharmacokinetics, pharmacodynamics and metabolism of MEAI by Shimshoni, David Nutt, Ezekiel Golan et al. One year later it was studied and reported on in another peer reviewed paper by Halberstadt et al. The aminoindane family of molecules was, perhaps, first chemically described in 1980.


      Alcohol substitute


      MEAI was an early candidate of alcohol replacement drugs that came to market during a late 2010s movement to replace alcohol with less-toxic alternatives spearheaded by British psychopharmacologist David Nutt rippling to the rest of Europe.
      In an act of gonzo journalism, Michael Slezak writing for New Scientist, tried and reported on his experience with MEAI after being provided with it by Dr Zee (Ezekiel Golan) after an interview Golan claimed he invented MEAI and originally intended MEAI to be sold as a legal high but instead indicated plans to work with David Nutt and his company DrugScience to develop MEAI further based on Golan's patents as a "binge behaviour regulator" and "alcoholic beverage substitute".
      In 2018, a company named Diet Alcohol Corporation of the Americas (DACOA) began openly marketing an MEAI-based drink called "Pace" for sale in the USA and Canada. Pace was described as a 50ml bottle containing 160 mg of MEAI in mineral water. Distribution halted after Health Canada released a warning indicating the substance was considered illegal to market for consumption in Canada due to structural similarity to amphetamine. In a December 2018 article by CBC News, Ezekiel Golan (Dr Z/Dr Zee) was interviewed and publicly came out as the "lead scientist" of Pace claiming "tens of thousands" of bottles were already sold in Canada. Golan claimed the MEAI featured in Pace was "manufactured in India" and "bottled in Delaware". Health Canada provided a statement to CBC News stating "Pace is an illegal and unauthorized product in Canada."


      Pharmaceutical development


      On May 26, 2022, MEAI was prepared for FDA registration by Clearmind Medicine Inc.; Clearmind Medicine claims wide intellectual property holdings to Ezekiel Golan's patents. In March 2022 Clearmind Medicine announced supportive evidence from animal studies in mice attesting to suppression of alcohol consumption. In June 2022 Clearmind Medicine announced promising results from animal studies that showed promise for treating cocaine addiction with MEAI.
      MEAI, under the developmental code name CMND-100, is under development by Clearmind Medicine for the treatment of alcoholism, cocaine use disorder, metabolic syndrome, and obesity. As of October 2024, it is in the preclinical stage of development for these indications.


      See also


      MMAI
      5-IAI
      MDAI
      MDMAI
      NM-2-AI
      TAI
      Pagoclone


      References




      External links


      Information Video About Alcohol Consumption

    Kata Kunci Pencarian: meai

    mesin slotmesirmesin cucimesin pencari selain googlemesin128mesin4dmesin cuci 2 tabungisitotomesin cuci 1 tabungmesinkoin Search Results

    meai

    Daftar Isi

    MEAI - Wikipedia

    MEAI, also known as 5-methoxy-2-aminoindane (5-MeO-AI), is a monoamine releasing agent of the 2-aminoindane group. [1] It specifically acts as a selective serotonin releasing agent (SSRA). [1] The drug is under development for the treatment of alcoholism, cocaine use disorder, metabolic syndrome, and obesity under the developmental code name ...

    MEAI: The Non-Hallucinogenic Psychedelic with ... - Psychedelic …

    May 18, 2023 · MEAI is an innovative compound, a category nicknamed “Next-Gen” psychedelics, mostly due to the fact that it is not hallucinogenic. MEAI does not offer the “high” typically associated with psychedelics as a kind of spiritual or insightful experience.

    Clearmind Medicine

    MEAI: A New Psychoactive Molecule. 5-Methoxy-2-aminoindane, or "MEAI" MEAI exerts a euphoric alcohol-like experience and a reduced desire to consume alcoholic beverages with potential to change the lives of millions who struggle to drink in moderation.

    MEAI

    MEAI, also known as 5-methoxy-2-aminoindane, 5-MeO-AI, or Chaperon, belongs to the family of indane molecules. Its molecular structure made its initial, albeit implicit, appearance within a patent document back in 1998.

    The Science and IP Behind our Treatments - Clearmind Medicine

    5-Methoxy-2-aminoindane (MEAI) is a novel psychoactive aminoindane derivative, exerting euphoric, alcohol-like tipsy experience and reduced desire to consume alcoholic beverages.

    MEAI - Wikiwand

    MEAI, also known as 5-methoxy-2-aminoindane (5-MeO-AI), is a monoamine releasing agent of the 2-aminoindane group. It specifically acts as a selective serotonin...

    Clearmind Medicine

    Mar 13, 2024 · The active ingredient in CMND-100 is MEAI, an innovative, psychoactive and non-hallucinogenic molecule that has been reported to reduce the desire to consume alcoholic beverages, while exerting a slight euphoric alcohol-like experience.

    Pharmacokinetic and pharmacodynamic evaluation of 5-methoxy …

    Mar 15, 2018 · 5-Methoxy-2-aminoindane (MEAI) is a novel psychoactive aminoindane derivative, exerting euphoric, alcohol-like tipsy experience and reduced desire to consume alcoholic beverages.

    Toxicological evaluation of 5-methoxy-2-aminoindane (MEAI): …

    Mar 15, 2017 · 5-Methoxy-2-aminoindane (MEAI) is a psychoactive compound of the aminoindane class, which in recent years has been recreationally used by many people, who reported of a mild euphoric, alcohol-like tipsy experience and reduced desire to consume alcoholic beverages.

    MeAI

    First AI-driven Web3 lifestyle app - boost your health and wealth with GameFi and DeSci. Improve yourself, inspire others, earn. MeAI. Explained. Integrate MeAI routine! Socialize, make healthier choices and collect rewards. Join us on a journey as we strive towards MeAI app launch.